Posted by Michael Wonder on 31 Oct 2020
Gilead’s COVID-19 drug is mediocre. It will be a blockbuster anyway.
29 October 2020 - Gilead Sciences said Wednesday that remdesivir, which has been authorised for emergency use since the spring, brought in $873 million in revenues so far this year.
The United States reached a milestone, of sorts, when last week the FDA approved the first treatment for COVID-19.
